{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T17:46:46Z","timestamp":1744739206070},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T00:00:00Z","timestamp":1433462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00405-015-3673-y","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T15:40:49Z","timestamp":1433432449000},"page":"1629-1636","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab"],"prefix":"10.1007","volume":"273","author":[{"given":"Petr","family":"Szturz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pol","family":"Specenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Van Laer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Van Den Weyngaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob","family":"Corthouts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurens","family":"Carp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Van Marck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Vanderveken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan B.","family":"Vermorken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,5]]},"reference":[{"key":"3673_CR1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.mlg.0000161338.54515.b1","volume":"115","author":"MK Layland","year":"2005","unstructured":"Layland MK, Sessions DG, Lenox J (2005) The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope 115:629\u2013639","journal-title":"Laryngoscope"},{"key":"3673_CR2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2165\/11592540-000000000-00000","volume":"71","author":"BE Brockstein","year":"2011","unstructured":"Brockstein BE (2011) Management of recurrent head and neck cancer: recent progress and future directions. Drugs 71:1551\u20131559","journal-title":"Drugs"},{"key":"3673_CR3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","volume":"10","author":"AA Forastiere","year":"1992","unstructured":"Forastiere AA, Metch B, Schuller DE et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:1245\u20131251","journal-title":"J Clin Oncol"},{"key":"3673_CR4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00000421-200004000-00005","volume":"23","author":"J Janinis","year":"2000","unstructured":"Janinis J, Papadakou M, Xidakis E et al (2000) Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced\/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol 23:128\u2013131","journal-title":"Am J Clin Oncol"},{"key":"3673_CR5","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/1097-0142(20010401)91:7<1316::AID-CNCR1134>3.0.CO;2-0","volume":"91","author":"DM Shin","year":"2001","unstructured":"Shin DM, Khuri FR, Glisson BS et al (2001) Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91:1316\u20131323","journal-title":"Cancer"},{"key":"3673_CR6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116\u20131127","journal-title":"N Engl J Med"},{"key":"3673_CR7","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdm116","volume":"18","author":"P Specenier","year":"2007","unstructured":"Specenier P, Koppen C, Vermorken JB (2007) Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy. Ann Oncol 18:961\u2013962","journal-title":"Ann Oncol"},{"key":"3673_CR8","first-page":"359","volume":"61","author":"RE Wittes","year":"1977","unstructured":"Wittes RE, Cvitkovic E, Shah J, Gerold FP, Strong EW (1977) CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 61:359\u2013366","journal-title":"Cancer Treat Rep"},{"key":"3673_CR9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00263902","volume":"15","author":"RP Morton","year":"1985","unstructured":"Morton RP, Rugman F, Dorman EB et al (1985) Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 15:283\u2013289","journal-title":"Cancer Chemother Pharmacol"},{"key":"3673_CR10","doi-asserted-by":"crossref","unstructured":"Vermorken JB, Specenier P (2010) Optimal treatment for recurrent\/metastatic head and neck cancer. Ann Oncol 21(Suppl 7):vii252\u2013vii261","DOI":"10.1093\/annonc\/mdq453"},{"key":"3673_CR11","first-page":"4637","volume":"53","author":"Z Fan","year":"1993","unstructured":"Fan Z, Baselga J, Masui H, Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637\u20134642","journal-title":"Cancer Res"},{"key":"3673_CR12","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171\u20132177","journal-title":"J Clin Oncol"},{"key":"3673_CR13","doi-asserted-by":"crossref","unstructured":"Vermorken JB, Remenar E, Hitt R et al (2014) Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R\/M-SCCHN): 5-year follow-up data for the extreme trial. J Clin Oncol 32(suppl; abstr 6021)","DOI":"10.1200\/jco.2014.32.15_suppl.6021"},{"key":"3673_CR14","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","volume":"31","author":"P Blanchard","year":"2013","unstructured":"Blanchard P, Bourhis J, Lacas B et al (2013) Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 31:2854\u20132860","journal-title":"J Clin Oncol"},{"key":"3673_CR15","doi-asserted-by":"crossref","unstructured":"Buentzel J, de Vries A, Micke O (2007) Experience with cetuximab plus paclitaxel\/carboplatinum in primary platinum-resistant recurrent head and neck cancer. J Clin Oncol 25(suppl; abstr 6077)","DOI":"10.1200\/jco.2007.25.18_suppl.6077"},{"key":"3673_CR16","doi-asserted-by":"crossref","unstructured":"Guigay J, Fayette J, Dillies AF et al (2012) Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03. J Clin Oncol 30(suppl; abstr 5505)","DOI":"10.1200\/jco.2011.29.15_suppl.5567"},{"key":"3673_CR17","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20640","volume":"101","author":"A Argiris","year":"2004","unstructured":"Argiris A, Li Y, Forastiere A (2004) Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101:2222\u20132229","journal-title":"Cancer"},{"key":"3673_CR18","doi-asserted-by":"crossref","unstructured":"Rubin Grandis J, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824\u2013832","DOI":"10.1093\/jnci\/90.11.824"},{"key":"3673_CR19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/hed.2880130209","volume":"13","author":"J Santini","year":"1991","unstructured":"Santini J, Formento JL, Francoual M et al (1991) Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13:132\u2013139","journal-title":"Head Neck"},{"key":"3673_CR20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdt574","volume":"25","author":"JB Vermorken","year":"2014","unstructured":"Vermorken JB, Psyrri A, Mes\u00eda R et al (2014) Impact of tumor HPV status on outcome in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 25:801\u2013807","journal-title":"Ann Oncol"},{"key":"3673_CR21","doi-asserted-by":"crossref","first-page":"e103918","DOI":"10.1371\/journal.pone.0103918","volume":"9","author":"S Grisanti","year":"2014","unstructured":"Grisanti S, Almici C, Consoli F et al (2014) Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance. PLoS One 9:e103918","journal-title":"PLoS One"},{"key":"3673_CR22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1159\/000343636","volume":"35","author":"Y Park","year":"2012","unstructured":"Park Y, Kim DS, Park KH et al (2012) RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Onkologie 35:673\u2013682","journal-title":"Onkologie"},{"key":"3673_CR23","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-06-0913","volume":"12","author":"JC Sok","year":"2006","unstructured":"Sok JC, Coppelli FM, Thomas SM et al (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12:5064\u20135073","journal-title":"Clin Cancer Res"},{"key":"3673_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1758-3284-3-11","volume":"3","author":"NG Chau","year":"2011","unstructured":"Chau NG, Perez-Ordonez B, Zhang K et al (2011) The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol 3:11","journal-title":"Head Neck Oncol"},{"key":"3673_CR25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1756-0500-7-337","volume":"7","author":"C Boeckx","year":"2014","unstructured":"Boeckx C, Weyn C, Vanden Bempt I et al (2014) Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. BMC Res Notes 7:337","journal-title":"BMC Res Notes"},{"key":"3673_CR26","unstructured":"Vermorken JB, Remenar E, van den Weyngaert D et al (2012) Feasibility of cetuximab plus sequential platinum-based therapy (TPF\/CRT) in advanced squamous cell head and neck cancer (SCCHN): a randomized phase II study of the EORTC Head and Neck Cancer Group. Eur Arch Otorhinolaryngol 269:1311\u20131410 (abstract OP42)"},{"key":"3673_CR27","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2009.22.1333","volume":"27","author":"RI Haddad","year":"2009","unstructured":"Haddad RI, Tishler RB, Norris C et al (2009) Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 27:4448\u20134453","journal-title":"J Clin Oncol"},{"key":"3673_CR28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bjc.6600347","volume":"87","author":"N Tsavaris","year":"2002","unstructured":"Tsavaris N, Kosmas C, Vadiaka M et al (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87:21\u201327","journal-title":"Br J Cancer"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-015-3673-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00405-015-3673-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-015-3673-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T01:36:16Z","timestamp":1599096976000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00405-015-3673-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,5]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3673"],"URL":"https:\/\/doi.org\/10.1007\/s00405-015-3673-y","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,5]]}}}